Skip to main content
. 2020 Jun 10;12(6):1519. doi: 10.3390/cancers12061519

Figure 1.

Figure 1

The combination of pazopanib and trametinib modulated MAPK and PI3K/Akt pathways in seven osteosarcoma cell lines. (A), Flow cytometry analysis of RTKs expression in seven osteosarcoma cell lines. (B), Representative western blot analysis of P-Akt (Ser473), P-ERK1/2 (Thr202/Tyr204), Akt, and ERK1/2 at basal conditions and after 24 h of treatment with pazopanib, trametinib, and their combination. Vinculin expression was evaluated as a loading control. (C,D), Densitometric analysis of protein band intensity of P-Akt (C) and P-ERK1/2 (D) normalized to housekeeping bands. Data are expressed as mean ± SD. Independent experiments were performed three times in seven osteosarcoma cell lines. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. controls. NT = not treated, P = pazopanib, T = trametinib, P + T = pazopanib + trametinib combination.